The “New Normal” for Clinical Research in the Wake of COVID-19/media/informa-shop-windo… ·...

We surveyed 100 clinical trial investigators in the Citeline Engage network to gauge the “new normal” and expectations for clinical research The “New Normal” for Clinical Research in the Wake of COVID-19 30% 3 months 30% 6 months 27% Expect normalization by Early 2021 Nearly half expect to return to business as usual COVID-19 impact on ability to serve as a clinical trial investigator Other 3% Negative 39% Positive 7% Neutral 51% 39% of investigators anticipate their capacity for clinical research to decrease due to COVID-19, which should be accounted for during planning 7% believe clinical research will be a greater focus Also, 64% of investigators said that COVID-19 will not impact which trials they will take on in the future But business as usual will evolve with most investigators expecting various changes to clinical trials 69% More hybrid/ virtual trial designs 35% Leaner protocols with less endpoints 24% Greater industry focus on patient burden 6% Other/No change of investigators expect patient enrollment will become even more difficult; but at the same time, believe a shift toward hybrid/virtual trial designs will increase patient interest in and access to clinical trials. As a result, recruiting experienced investigators with significant patient counts will be more important than ever. About a third of clinical trial investigators are somewhat or not comfortable with digital tools and software to support virtual trials – an important topic to address with investigators during trial planning. Note: Total percentage does not sum to 100% due to rounding 5% Not comfortable at all 26% Somewhat comfortable 35% Comfortable 35% Very comfortable Comfort level with digital tools/software to support virtual trials Only 9% of investigators are very confident that Sponsors and CROs can shift toward hybrid/virtual trials quickly Nearly 50% of investigators are not experiencing delays in ethics committee/IRB reviews for non-COVID-19 trials Unknown 26% No, there are not delays 45% Yes, there are delays 29% 30% 49% 22% Additional 1-2 weeks Additional 3-5 weeks More than 5 weeks 69% 44% Source: Survey results of Citeline Engage investigators conducted in May 2020 Expect normalization within next For those experiencing delayed reviews, timelines are typically extended by an additional 3-5 weeks 87% of clinical trial investigators expect trial operations to normalize by early 2021

Upload
others
Category

Documents
view
0
download
0

Embed Size (px):

Transcript of The “New Normal” for Clinical Research in the Wake of COVID-19/media/informa-shop-windo… ·...

We surveyed 100 clinical trial investigators in the Citeline Engage network to gauge the “new normal” and expectations for clinical research

The “New Normal” for Clinical Research in the Wake of COVID-19

30%

3 months

30%

6 months

27%Expect

normalization by

Early 2021

Nearly half expect to return to business as usual

COVID-19 impact on

ability to serve as a clinical trial

investigator

Other 3%

Negative 39%

Positive7%

Neutral 51%

39% of investigators anticipate their capacity for clinical

research to decrease due to COVID-19, which

should be accounted for during planning

7% believe clinical

research will be a

greater focus

Also, 64% of investigators

said that COVID-19 will

not impact which trials they will

take on in the future

But business as usual will evolve with most investigators expecting various

changes to clinical trials

69%More hybrid/

virtual trial designs

35%Leaner protocols

with less endpoints

24%Greater industry focus on patient

burden

6%Other/No

change

of investigators expect patient enrollment will become even more difficult; but at the same time,

believe a shift toward hybrid/virtual trial designs will increase patient interest in and access to clinical trials. As a result, recruiting experienced investigators with significant patient counts will be more important than ever.

About a third of clinical trial investigators are somewhat or not comfortable with digital tools and software to support virtual trials – an important topic to address with investigators during trial planning.

Note: Total percentage does not sum to 100% due to rounding

5% Not comfortable at all26% Somewhat comfortable

35% Comfortable35% Very comfortable

Comfort level with digital tools/software to support virtual trials

Only 9% of investigators are very confident that Sponsors and CROs can shift toward hybrid/virtual trials quickly

Nearly 50% of investigators are not experiencing delays in ethics committee/IRB

reviews for non-COVID-19 trials

Unknown 26%

No, there are not delays 45%

Yes, there are delays 29%

30%

49%